Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025

References

• GLOBOCAN. Cancer today [Internet]. [cited 2021 Jan 19]. Available from: http://gco.iarc.fr/today/home
   Google Scholar
• SEER Cancer Stat Facts [Internet]. SEER. [cited 2021 Feb 1]. Available from: https://seer.cancer.gov/statfacts/index.html
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.4.2020. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. [cited 19 Jan 2021]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 (Suppl 5):v116–125.
   PubMed Web of Science ®Google Scholar
• Purdum A, Tieu R, Reddy SR, et al. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229–1236.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298–308.
   PubMed Web of Science ®Google Scholar
• Halwani AS, Chien H-C, Morreall DK, et al. Survival patterns in patients with relapsed or refractory diffuse large B cell lymphoma: treatment trajectories and responses after the first relapse. Blood. 2019;134(Supplement_1):1622.
   Google Scholar
• Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74.
   PubMed Web of Science ®Google Scholar
• Katz SJ, Hawley ST, Bondarenko I, et al. Oncologists’ influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? Breast Cancer Res Treat. 2017;165(3):751–756.
   PubMed Web of Science ®Google Scholar
• Kurian AW, Bondarenko I, Jagsi R, et al. Recent trends in chemotherapy use and oncologists’ treatment recommendations for early-stage breast cancer. JNCI J Natl Cancer Inst. 2018;110(5):493–500.
   Web of Science ®Google Scholar
• CancerMPact. Treatment Architecture [Internet]. 2018. [cited 2019 Nov 15]. Available from: Kantar, www.cancermpact.com
   Google Scholar
• Le Guyader-Peyrou S, Defossez G, Dantony E, et al. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 – Hémopathies malignes: Étude à partir des registres des cancers du réseau Francim [Internet]. France: Sante publique; 2019. p. 169. [cited 2021 Mar 2] Available from: https://www.santepubliquefrance.fr/docs/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-metropolitaine-entre-1990-et-2018-volume-2-hemopathies-malignes
   Google Scholar
• AIRTUM ITACAN. Cancer in Italy, Version 2.0. Italian Association of Cancer Registries [Internet]. [cited 2014 Aug 14]. Available from: http://www.registri-tumori.it
   Google Scholar
• German Centre for Cancer Registry Data, Robert Koch Institute. Database Query with estimates for cancer incidence, prevalence and survival in Germany, based on data of the population-based cancer registries ( Mortality data provided by the Federal Statistical Office. [Internet]. [cited 2019 Dec 17]. Available from: www.krebsdaten.de/database
   Google Scholar
• Bray F, Colombet M, Mery L, et al. editors. Cancer Incidence in Five Continents. Vol. XI [Internet]. Lyon: International Agency for Research on Cancer; 2017. p. 15. [cited 2021 Mar 2]. Available from: https://ci5.iarc.fr, [cited February 2018]; Available from: https://publications.iarc.fr/Databases/Iarc-Cancerbases/Cancer-Incidence-In-Five-Continents-Vol.-XI-2017.
   Google Scholar
• Cancer Research UK. Cancer Statistics for the UK [Internet]. [cited 2021 Mar 2]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk
   Google Scholar
• SEER*Stat Database: NPCR and SEER Incidence. – U.S. Cancer Statistics Public Use Database, Nov 2018 submission (2001–2016). United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2019, based on the November 2018 submission.
   Google Scholar
• U.S. Census Bureau. 2014 to 2060 Population Projections based on Census 2010 (released 2014) [Internet]. [cited 2019 Nov 15]. Available from: http://www.census.gov/population/projections/data/national/
   Google Scholar
• United Nations, Department of Economic and Social Affairs, Population Division. New York: World Population Prospects: The 2015 Revision. 2015.
   Google Scholar
• Instituto Nacionale de Estadistica. [cited 2016 Sep 15]. Available from: www.ine.es
   Google Scholar
• EUROCARE-5 Database. Survival of Cancer Patients in Europe The EUROCARE-5 Study [Internet]. [cited 2019 Feb 15]. Available from: https://w3.iss.it/site/EU5Results/
   Google Scholar
• Solal-Céligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–3853.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–435.
   PubMed Web of Science ®Google Scholar
• Ionescu-Ittu R, Shang A, Velde NV, et al. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world. J Comp Eff Res. 2019;8(13):1067–1075.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Fedewa SA, Chen AY, et al. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1520–1530.
   PubMed Web of Science ®Google Scholar
• Arboe B, Olsen MH, Gørløv JS, et al. Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study. Clin Epidemiol. 2019;11:207–216.
   PubMed Web of Science ®Google Scholar
• Rovira J, Valera A, Colomo L, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94(5):803–812.
   PubMed Web of Science ®Google Scholar
• Patmore R, Roman E, Smith A, et al. Patient’s age and treatment for haematological malignancy: a report from the haematological malignancy research network. University of York: Haematological Malignancy Research Network; 2014.
   Google Scholar
• Ayers EC, Margolis D, Landsburg DJ. Real world outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma receiving palliative intent therapies. Clin Lymphoma Myeloma Leuk. 2020;20(10):661–667.
   PubMed Web of Science ®Google Scholar
• Link BK, Day B-M, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660–663.
   PubMed Web of Science ®Google Scholar
• Albarmawi H, Nagarajan M, Onukwugha E, et al. Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients. Future Oncol Lond Engl. 2020;16(8):353–365.
   PubMed Web of Science ®Google Scholar
• Vargo JA, Gill BS, Balasubramani GK, et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121(18):3325–3334.
   PubMed Web of Science ®Google Scholar
• Wang H-I, Roman E, Crouch S, et al. A generic model for follicular lymphoma: predicting cost, life expectancy, and quality-adjusted-life-year using UK population-based observational data. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2018;21(10):1176–1185.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473–2481.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33(23):2516–2522.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905.
   PubMed Web of Science ®Google Scholar
• Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 2020;136(Supplement 1):42–43.
   Google Scholar
• Phillips TJ, Olszewski AJ, Munoz J, et al. Mosunetuzumab, a novel CD20/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):37–38.
   Google Scholar